Polyps are abnormal development of tissues projecting from a mucous membrane, normally originating in the uterus, urinary bladder, sinus, ear, nose, stomach, or colon. However, these can form in other places in the body where mucous membranes are present. Most polyps are non-cancerous or benign; however, some are premalignant. Premalignant polyps is one of the factor which can trigger the cancer development. Generally, the risk of cancer is related to the size of polyps, larger the polyps, higher the risk of cancer, particularly with premalignant polyps. Diagnosis of polyps is difficult and screening is the only reliable measure to detect it. Symptoms related to polyps are vomiting, nausea, constipation, diarrhea, pain, dysmenorrhea, vaginal bleeding, and irregular periods in women.
Cause of polyps can vary based on location. For instance, polyps of the throat are a result of an injury from shouting loudly or damage from a breathing tube. In some cases, physicians cannot determine the actual cause of polyps. Some known causes of polyps are excess estrogen, chronic stomach inflammation, mutation in the genes of colon cells, tumor, cyst, foreign object, and inflammation.
Polyps develop by quickly dividing cells, which is similar to growth of cancer cells. Hence, these can turn cancerous although most polyps are benign in nature. Polyps are major risk factors of colon cancer and colorectal cancer initiates as polyps, a growth in the inside lining of the rectum or colon. Adenoma, a certain kind of polyp that has greater risk of developing into colorectal cancer, is the third most common type of non-skin cancer in both men and women. It is the second major cause of cancer deaths in the U.S. after lung cancer. According to the U.S. Department of Health and Human Services, around 134,490 people in the U.S. were diagnosed with colorectal cancer in 2016 and around 49,190 people succumbed due to the disease.
Rise in awareness about polyps and its potentially cancerous nature and increase in screening are the major factors boosting the growth of the global polyps market. Increase in geriatric population is another major factor driving the global market. However, several risks associated with polyps such as blood loss and infection during surgery, personal or family history of polyps, and no symptoms are the major restraints of the global market. High cost of nominally invasive surgeries and less health care spending in developing regions are the other factors restraining the global polyps market.
The global polyps market can be segmented based on type of polyps, diagnosis, treatment, end-user, and region. In terms of type of polyps, the global market can be classified into premalignant, laryngeal, nasal, cervical, endometrial, and digestive. Based on diagnosis, the global polyps market can be categorized into computed tomography, double contrast barium enema, sigmoidoscopy, colonoscopy, stool and occult blood test, and others. In terms of treatment, the global market can be bifurcated into drugs and surgery. Drugs can be divided into painkillers, hormonal drugs, and others. Based on end-user, the global polyps market can be classified into hospitals & clinics, academic & research institutes, and others.
In terms of region, the global polyps market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global polyps market due to availability of advanced drug formulations. Awareness among people about polyps is also a major factor boosting the market in the region. The polyps market in Asia Pacific is anticipated to expand at a rapid pace due to increase in geriatric population. Lack of awareness about polyps and unavailability of advanced medication and surgical procedures in underdeveloped countries such as Lebanon, Syria, Cyprus, Turkey, and Iraq are likely to restrain the growth of the polyps market in Middle East & Africa.
Top players operating in the global polyps market are Novartis AG, Teva Pharmaceutical Industries Ltd., and Pfizer Inc., among others.
No comments:
Post a Comment